BERKELEY, Calif., Oct. 09, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three
distinct immunotherapy technologies, today announced data presentations relating to its technology platforms to be given at the
Society for Immunotherapy of Cancer’s 32nd Annual Meeting taking place in National Harbor, Maryland, November 8-12,
2017.
| Poster 335: |
Characterization of a novel differentiated anti-CTLA-4 antibody
(ADU-1604) in vitro and in vivo |
| |
Date/Time: Friday, November 10, 12:30 p.m. to 2:00 p.m. EST |
| |
Poster Hall Location: Prince George’s Exhibition Hall DE |
| |
|
| Poster 61: |
Cellular and genomic disease signature of peripheral blood mononuclear
cells in patients with malignant pleural mesothelioma |
| |
Date/Time: Friday, November 10, 12:30 p.m. to 2:00 p.m. EST |
| |
Poster Hall Location: Prince George’s Exhibition Hall DE |
| |
|
| Poster 133:
|
A heterologous prime-boost vaccination strategy combining a Listeria
and DNA-based vaccine encoding prostatic acid phosphatase (PAP) elicits a strong antigen-specific, anti-tumor response |
| |
Date/Time: Friday, November 10, 12:30 p.m. to 2:00 p.m. EST |
| |
Poster Hall Location: Prince George’s Exhibition Hall DE |
Per SITC guidelines, abstracts are embargoed until 8:00 a.m. EST on November 7, 2017. To view abstracts, please visit the
SITC website at https://www.sitcancer.org/2017/abstracts/info.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of
therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the
body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and
infectious diseases. Aduro's LADD technology platform is based on proprietary attenuated strains of Listeria that have been
engineered to express tumor-associated antigens to induce specific and targeted immune responses. This platform is being developed
as a treatment for multiple indications, including mesothelioma, gastric, ovarian, lung and prostate cancers. Additionally, a
personalized form of LADD, or pLADD, is in Phase 1 development utilizing tumor neoantigens that are specific to an individual
patient’s tumor. Aduro's STING Pathway Activator platform is designed to activate the STING receptor in immune cells, resulting in
a potent tumor-specific immune response. ADU-S100 is the first STING Pathway Activator compound to enter the clinic and is
currently being evaluated in both a Phase 1 monotherapy study as well as a Phase 1b combination study with an anti-PD1 immune
checkpoint inhibitor. Aduro’s B-select monoclonal antibody platform is comprised of a number of immune modulating assets in
research and preclinical development, including BION-1301, an anti-APRIL antibody. Aduro is collaborating with leading global
pharmaceutical companies to expand its products and technology platforms. For more information, please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations
concerning, among other things, our technology platforms, plans, and the potential for eventual regulatory approval of our product
candidates. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,”
“anticipate,” “intend,” “could,” “project,” “seek”, “expect” or the negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could
cause actual results and events to differ materially from those anticipated, including, but not limited to, our history of net
operating losses and uncertainty regarding our ability to achieve profitability, our ability to develop and commercialize our
product candidates, our ability to use and expand our technology platforms to build a pipeline of product candidates, our ability
to obtain and maintain regulatory approval of our product candidates, our inability to operate in a competitive industry and
compete successfully against competitors that have greater resources than we do, our reliance on third parties, and our ability to
obtain and adequately protect intellectual property rights for our product candidates. We discuss many of these risks in
greater detail under the heading “Risk Factors” contained in our quarterly report on Form 10-Q for the quarter ended June 30, 2017,
which is on file with the Securities and Exchange Commission. Any forward-looking statements that we make in this press release
speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the date of this press release.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
Media Contact:
Susan Lehner
510 809 2137
press@aduro.com
